Real-World tofacitinib study in ulcerative colitis ends early

NCT ID NCT05069259

Terminated Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well the drug tofacitinib (Xeljanz) works for people with moderate to severe ulcerative colitis in everyday medical practice in Switzerland. It measured symptom improvement and gut inflammation using stool samples. The study was small with 18 participants and was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tofacitinib (Xeljanz)
What this could lead to: If successful, this study could confirm that tofacitinib works well in everyday practice for people with ulcerative colitis, helping doctors make better treatment decisions.
What could go wrong: This was a small, terminated study with only 18 participants, so results may not be reliable or apply to everyone. Tofacitinib also carries risks like infections and blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS

Contacts and locations

Locations

Centre Fribourgeois de Gastroenterologie

Fribourg, Switzerland
Clarunis, Universitätsspital

Basel, Switzerland
Kantonsspital Baselland

Liestal, Switzerland
Kantonsspital St, Gallen

Sankt Gallen, Canton of St. Gallen, 9007, Switzerland
Verein IBD Study Group

Bern, CH - 3012, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.